{
  "paper_id": "PMC7337227",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337227/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1. Existing UK DMO pathway.",
      "caption": "Pathway based on CRT and lens status. CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ccf14d6f6fa5/41433_2020_961_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ccf14d6f6fa5/41433_2020_961_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ccf14d6f6fa5/41433_2020_961_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ccf14d6f6fa5/41433_2020_961_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ccf14d6f6fa5/41433_2020_961_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7337227/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ccf14d6f6fa5/41433_2020_961_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2. Existing UK DMO ‘anti-VEGF first-line’ pathway: based on NICE TAs for eyes with CFT > 400 μm.",
      "caption": "NICE The National Institute for Health and Care Excellence; VEGF vascular endothelial growth factor.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ef09904e0da6/41433_2020_961_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ef09904e0da6/41433_2020_961_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ef09904e0da6/41433_2020_961_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ef09904e0da6/41433_2020_961_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ef09904e0da6/41433_2020_961_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7337227/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/ef09904e0da6/41433_2020_961_Fig2_HTML.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Fig. 4. Consensus Recommended Pathway for Management of Centre-involving DMO.",
      "caption": "CFT central foveal thickness; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/89e4abdb2f0a/41433_2020_961_Fig4_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/89e4abdb2f0a/41433_2020_961_Fig4_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/89e4abdb2f0a/41433_2020_961_Fig4_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/89e4abdb2f0a/41433_2020_961_Fig4_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/89e4abdb2f0a/41433_2020_961_Fig4_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7337227/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b389/7337227/89e4abdb2f0a/41433_2020_961_Fig4_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CFT central foveal thickness; CNV choroidal nevoascular membrane; DMO diabetic macular oedema; VEGF vascular endothelial growth factor.Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In the current pathway for DMO in the UK, there is no agreement in terms of assessing treatment response (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "NICE recommends pharmacological therapies for DMO in eyes with CRT >400 μm (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The consideration for switching to intravitreal steroid treatment for insufficiently responsive eyes is discussed above (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ozurdex may be replaced with Iluvien later, if required. (Level 2, B)\n\nWhere the eye is NOT pseudophakic, and there is no significant cataract, and the DMO is chronic or inadequately responsive to anti-VEGFs, or the patient is pregnant or has other contraindications to anti-VEGF therapies including recent cardiovascular events, it is appropriate to consider dexamethasone implant (Ozurdex) injection. (Level 2, B)\nTriamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Triamcinolone is not recommended for routine use as it is not licensed for intravitreal injection in the UK and has a shorter duration of action as well as a different safety profile from intravitreal dexamethasone or fluocinolone implant. (Level 1, A) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 50,
    "images_downloaded": 3,
    "tables_filtered": 37
  }
}